News
SESN
0.6288
0.00%
0.0000
Carisma Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Reuters · 08/10/2023 19:07
BRIEF-Carisma Therapeutics Files Prospectus For Resale Of 3.73 Mln Shares Of Common Stock - SEC Filing
Reuters · 04/17/2023 21:49
BRIEF-Carisma Therapeutics Inc Files For Mixed Shelf Of Upto $300 Mln – SEC Filing
Reuters · 04/17/2023 21:49
More
Webull provides a variety of real-time SESN stock news. You can receive the latest news about Sesen Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SESN
Carisma Therapeutics Inc., formerly Sesen Bio, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The Company's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.